15th February 2018
MDxHealth Notice of Financial Year 2017 Results
IRVINE, CA, and HERSTAL, BELGIUM – February 15, 2018 – MDxHealth SA (Euronext: MDXH.BR) or the “Company” today announced that it will release its full year results for the financial year ended 31 December 2017 on 22 February 2018.
Dr. Jan Groen, Chief Executive Officer and Jean-Marc Roelandt, Chief Financial Officer, will host a conference call on the day of the results at 15:00 CET / 14:00 GMT / 06:00 PT. The call will be conducted in English and a replay will be available for 30 days.
To access the conference call, please dial one of the appropriate numbers below quoting the conference ID 9294798.
The Netherlands: 0207143545
The presentation will be made available on the Investors section of the MDxHealth website shortly before the call and can be accessed at: http://mdxhealth.com/investors.
To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled start timing.
MDxHealth is a multinational healthcare company, listed at the Brussels, Belgium stock exchange (Euronext: MDXH.BR) that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy.
ConfirmMDx for Prostate Cancer helps urologists identify low-risk men who may forego an unnecessary repeat biopsy and high-risk men who may benefit from intervention. ConfirmMDx is the first epigenetic, and only tissue-based test in the 2016 NCCN Guidelines for early detection of prostate cancer and that addresses false negative biopsy concerns. ConfirmMDx has qualified for Medicare reimbursement and covered by numerous private health insurance plans.
SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive 'liquid biopsy' method to assess a man's risk for prostate cancer. SelectMDx helps identify men at increased risk of harboring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test helps to reduce the need for MRI procedures and invasive prostate biopsies by up to 50%, thereby reducing healthcare costs.
The Company’s European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
Dr. Jan Groen, CEO
US: +1 949 812 6979
BE: +32 4 364 20 70
Consilium Strategic Communications (IR & PR)
Amber Fennell, Chris Welsh & Hendrik Thys
UK: +44 20 3709 5701
LifeSpring LifeSciences Communication, Amsterdam, The Netherlands
+31 6 538 16 427
Jean-Marc Roelandt, CFO
BE: +32 (0) 4 364 20 70
NL: +31 (0) 88 327 2727
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.